Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma:: A multicenter study of 412 patients

被引:56
作者
Decaens, Thomas
Roudot-Thoraval, Francoise
Bresson-Hadni, Solange
Meyer, Carole
Gugenheim, Jean
Durand, Francois
Bernard, Pierre-Henri
Boillot, Olivier
Compagnon, Philippe
Calmus, Yvon
Hardwigsen, Lean
Ducerf, Christian
Pageaux, Georges Philippe
Dharancy, Sebastien
Chazouilleres, Olivier
Cherqui, Daniel
Duvoux, Christophe
机构
[1] Hop Henri Mondor, Serv Hepatol & Gastroenterol, AP HP, Unite INSERM 581,Unite Transplantat Hepat, F-94010 Creteil, France
[2] Hop Henri Mondor, Dept Sante Publ, AP HP, Creteil, France
[3] Hop Jean Minjoz, Serv Hepatol, F-25030 Besancon, France
[4] Hop Hautefeuille, Transplantat Serv, Strasbourg, France
[5] Hop Archet 2, Serv Chirurg Digest, Nice, France
[6] Hop Beaujon, Serv Hepatol, AP HP, Clichy, France
[7] Hop Pellegrin, Serv Hepatol & Gastroenterol, F-33076 Bordeaux, France
[8] Hop Edouard Herriot, Serv Chirurg Digest, Lyon, France
[9] Hop Pontchaillou, Serv Chirurg Digest, Rennes, France
[10] Hop Cochin, AP HP, Serv Chirurg Digest, F-75674 Paris, France
[11] Hop Conception, Serv Chirurg Digest, Marseille, France
[12] Hop Croix Rousse, Serv Chirurg Digest, F-69317 Lyon, France
[13] Hop St Eloi, Federat Medicochirurg Malad Appareil Digest, Montpellier, France
[14] Hop Claude Huriez, Serv Hepatol & Gastroenterol, Lille, France
[15] Hop St Antoine, Serv Hepatol, AP HP, F-75571 Paris, France
关键词
immunosuppression; hepatocellular carcinoma; tumor differentiation; liver transplantation;
D O I
10.3748/wjg.v12.i45.7319
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To assess pre-orthotopic liver transplantation (OLT) factors that could be evaluated pre-operatively or controlled post-operatively associated with hepatocellular carcinoma (HCC) recurrence and disease-free survival after liver transplantation (LT). METHODS: Four hundred and twelve patients transplanted for HCC between 1988 and 1998 in 14 French centers, who survived the postoperative period were studied. Kaplan Meier estimates were calculated for 24 variables potentially associated with recurrence of HCC. Uni- and multivariate analyses were conducted to identify independent predictors of recurrence. RESULTS: Overall 5-year disease-free survival was 57.1%. By univariate analysis, variables associated with disease-free survival were: presence of cirrhosis (P = 0.001), etiology of liver disease (P = 0.03), alpha fetoprotein level (< 200, 200 to 2000, or > 2000; P < 0.0001), gamma-GT activity (N, N to 2N or > 2N; P = 0.02), the number of nodules (1, 2-3 or >= 4; P = 0.02), maximal diameter of the largest nodule (< 3 cm, 3 to 5 cm or > 5 cm; P < 0.0001), the sum of the diameter of the nodules (< 3 cm, 3 to 5 cm, 5 to 10 cm or > 10 cm; P < 0.0001), bilobar location (P = 0.01), preoperative portal thrombosis (P < 0.0001), peri-operative treatment of the tumor (P = 0.002) and chemoembolization (P = 0.03), tumor differentiation (P = 0.01), initial type of calcineurin inhibitor (P = 0.003), the use of antilymphocyte antibodies (P 0.02), rejection episodes (P = 0.003) and period of LT (P < 0.0001). By multivariate analysis, 6 variables were independently associated with HCC recurrence: maximal diameter of the largest nodule (P < 0.0001), time of LT (P < 0.0001), tumor differentiation (P < 0.0001), use of anti-lymphocyte antibody (ATG) or anti-CD3 antibody (OKT3) (P = 0.005), preoperative portal thrombosis (P = 0.06) and the number of nodules (P = 0.06). CONCLUSION: This study identifies immunosuppression, through the use of ATG or OKT3, as a predictive factor of tumor recurrence, and confirms the prognostic value of tumor differentiation. (c) 2006 The WJG Press. All rights reserved.
引用
收藏
页码:7319 / 7325
页数:7
相关论文
共 33 条
[1]  
[Anonymous], INV BOOKL PROT
[2]   LIVER RESECTION VERSUS TRANSPLANTATION FOR HEPATOCELLULAR-CARCINOMA IN CIRRHOTIC-PATIENTS [J].
BISMUTH, H ;
CHICHE, L ;
ADAM, R ;
CASTAING, D ;
DIAMOND, T ;
DENNISON, A .
ANNALS OF SURGERY, 1993, 218 (02) :145-151
[3]  
Ceriello A, 1994, Transpl Int, V7 Suppl 1, pS204
[4]  
Chapoutot C, 1999, GASTROEN CLIN BIOL, V23, P552
[5]   Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma [J].
Cillo, U ;
Vitale, A ;
Bassanello, M ;
Boccagni, P ;
Brolese, A ;
Zanus, G ;
Burra, P ;
Fagiuoli, S ;
Farinati, F ;
Rugge, M ;
D'Amico, DF .
ANNALS OF SURGERY, 2004, 239 (02) :150-159
[6]  
Deuffic S, 1998, LANCET, V351, P214, DOI 10.1016/S0140-6736(05)78179-4
[7]  
EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO
[8]  
2-E
[9]   Rising incidence of hepatocellular carcinoma in the United States [J].
El-Serag, HB ;
Mason, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) :745-750
[10]   Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma [J].
Freise, CE ;
Ferrell, L ;
Liu, T ;
Ascher, NL ;
Roberts, JP .
TRANSPLANTATION, 1999, 67 (04) :510-513